Clinical implications of mucosal healing in the management of patients with inflammatory bowel disease

Digestive and Liver Disease

Volumn 45, Issue 12, 2013, Pages 986-991

  Orlando, Ambrogio ^a   Guglielmi, Francesco William ^b   Cottone, Mario ^a   Orlando, Emanuele ^a   Romano, Claudia ^a   Sinagra, Emanuele ^a,c  

^a UNIVERSITY OF PALERMO   (Italy)

^b San Nicola Pellegrino Hospital Trani   (Italy)

^c Fondazione Istituto San Raffaele G Giglio   (Italy)

Author keywords

Clinical remission; Inflammatory Bowel Disease; Mucosal healing

Indexed keywords

ADALIMUMAB; BIOLOGICAL PRODUCT; INFLIXIMAB;

CROHN DISEASE; DISEASE COURSE; ENTERITIS; HEALING; HEALTH CARE COST; HOSPITALIZATION; HUMAN; INTESTINE MUCOSA; PRIORITY JOURNAL; QUALITY OF LIFE; REMISSION; REVIEW; SYMPTOM; ULCERATIVE COLITIS;

CLINICAL REMISSION; INFLAMMATORY BOWEL DISEASE; MUCOSAL HEALING;

COLITIS, ULCERATIVE; CROHN DISEASE; ENDOSCOPY, GASTROINTESTINAL; HUMANS; INTESTINAL MUCOSA; MAINTENANCE CHEMOTHERAPY; RECURRENCE; REMISSION INDUCTION; WOUND HEALING;

EID: 84887210548     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2013.07.005     Document Type: Review

References (51)

1. Abraham C., Cho J.H. Inflammatory bowel disease. New England Journal of Medicine 2009, 361:2066-2078.
2. Kappelman M.D., Rifas-Shiman S.L., Kleinman K., et al. The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States. Clinical Gastroenterology and Hepatology 2007, 5:1424-1429.
3. Loftus E.V. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 2004, 126:1504-1517.
4. Peyrin Birulet L., Loftus E.V., Colombel J.F., Sandborn W.J. The natural history of adult Crohn's disease in population-based cohorts. American Journal of Gastroenterology 2010, 105:289-297.
5. Langholz E. Ulcerative colitis. An epidemiological study based on a regional inception cohort, with a special reference to disease course and prognosis. Danish Medical Bulletin 1999, 46:400-415.
6. Bassi A., Dodd S., Williamson P., Bodger K. Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study. Gut 2004, 53:1471-1478.
7. Ha C., Kornbluth A. Mucosal healing in inflammatory bowel disease: where do we stand?. Current Gastroenterology Reports 2010, 12:471-478.
8. Iacucci M., Ghosh S. Looking beyond symptom relief: evolution of mucosal healing in inflammatory bowel disease. Therapeutic Advances in Gastroenterology 2011, 4:129-143.
9. Kappelmann M., Rifas-Shiman S.L., Kleinman K., et al. The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States. Clinical Gastroenterology and Hepatology 2007, 5:1424-1429.
10. Osterman M.T. Mucosal healing in Inflammatory Bowel Disease. Journal of Clinical Gastroenterology 2013, 47:212-221.
11. Smedh K., Olaison G., Franzén L., et al. The endoscopic picture reflects transmural inflammation better than endoscopic biopsy in Crohn's disease. European Journal of Gastroenterology and Hepatology 1996, 8:1189-1193.
12. Modigliani R., Mary J.Y., Simon J.F., et al. Clinical, biological and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives. Gastroenterology 1990, 98:811-818.
13. Rutgeerts P., Geboes K., Vantrappen G., et al. Predictability of the postoperative course of Crohn's Disease. Gastroenterology 1990, 99:956-963.
14. Allez M., Lemann M., Bonnet J., et al. Long-term outcome of patients with active Crohn's Disease exhibiting extensive and deep ulcerations at colonoscopy. American Journal of Gastroenterology 2002, 97:947-953.
15. Froslie K.F., Jahnsen J., Moum B.A., et al. Mucosal healing in inflammatory bowel disease: results from a population-based cohort. Gastroenterology 2007, 133:412-422.
16. Feagan B.G., Lemann M., Befrits R., et al. Recommendations for the treatment of Crohn's disease with tumor necrosis factor antagonists: an expert consensus report. Inflammatory Bowel Diseases 2012, 18:152-160.
17. Travis S.P.L., Schnell D., Krzeski P., et al. Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut 2012, 61:535-542.
18. Samuel S., Bruining D.H., Loftus E.V., et al. Validation of the ulcerative colitis colonoscopic index of severity and its correlation with disease activity measures. Clinical Gastroenterology and Hepatology 2013, 11:49-54.
19. Wright R., Truelove S.R. Serial rectal biopsy in ulcerative colitis during the course of a controlled therapeutic trial of various diets. American Journal of Digestive Diseases 1966, 11:847-857.
20. Hay J.W., Hay A.R. Inflammatory Bowel disease: costs-of-illness. Journal of Clinical Gastroenterology 1992, 14:309-317.
21. Colombel J.F., Sandborn W.J., Rutgeerts P., et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's Disease: the CHARM trial. Gastroenterology 2007, 132:52-65.
22. Schnitzler F., Fidder H., Ferrante M., et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. Inflammatory Bowel Diseases 2009, 15:1295-1301.
23. Carbonnel F., Lavergne A., Lèmann M., et al. Colonoscopy of acute colitis. A safe and reliable tool for assessment of severity. Digestive Diseases and Sciences 1994, 39:1550-1557.
24. Solberg I.C., Lygren I., Jahnsen J., et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN study). Scandinavian Journal of Gastroenterology 2009, 44:431-440.
25. Louis E., Vernier Massouille G., Grimaud J., et al. Infliximab discontinuation in Crohn's disease patients in stable remission on combined therapy with immunosuppressors: interim analysis of a prospective cohort study. Gut 2008, 57:A66.
26. Louis E., Vernier Massouille G., Grimaud J., et al. Infliximab discontinuation in Crohn's disease patients in stable remission on combined therapy with immunosuppressors: a prospective ongoing cohort study. Gastroenterology 2009, 136:A146.
27. Lèmann M., Mary J.Y., Colombel J.F., et al. A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine. Gastroenterology 2005, 128:1812-1818.
28. Rutgeerts P., Van Assche G., Sandborn W.J., et al. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology 2012, 142:1102-1111.
29. Allez M., Lèmann M. Role of endoscopy in predicting the disease course in inflammatory bowel disease. World Journal of Gastroenterology 2010, 16:2626-2632.
30. Rutter M., Saunders B., Wilkinson K., et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004, 126:451-459.
31. Rutter M.D., Saunders B.P., Wilkinson K.H., et al. Cancer surveillance in longstanding ulcerative colitis: endoscopic appearance help predict cancer risk. Gut 2004, 53:1813-1816.
32. Ardizzone S., Cassinotti A., Duca P., et al. Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis. Clinical Gastroenterology and Hepatology 2011, 9:483-489.
33. Colombel J.-F., Rutgeerts P., Reinisch W., et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 2011, 141:1194-1201.
34. Meucci G., Fasoli R., Saibeni S., et al. Prognostic significance of endoscopic remission in patients with active ulcerative colitis treated with oral and topical mesalazine: a prospective, multicenter study. Inflammatory Bowel Diseases 2012, 18:1006-1010.
35. Thakkar K., Lucia C.J., Ferry G.D., et al. Repeat endoscopy affects patient management in pediatric inflammatory bowel disease. American Journal of Gastroenterology 2009, 104:722-727.
36. Van Assche G., Dignass A., Reinisch W., et al. The second European evidence-based consensus on the diagnosis and management of Crohn's Disease: special situations. Journal of Crohn's and Colitis 2010, 4:63-101.
37. Hebuterne X., Lèmann M., Bouhnik Y., et al. Endoscopic improvement of mucosal lesions in patients with moderate to severe Crohn's Disease following treatment with certolizumab pegol. Gut 2013, 62:201-208.
38. Neumann H., Mönkemüller K., Günther C., et al. Advanced endoscopic imaging for diagnosis of Crohn's Disease. Gastroenterology Research and Practice 2012, 301541.
39. Nishio T., Ando T., Maeda O., et al. Pit patterns in rectal mucosa assessed by magnifying colonoscope are predictive of relapse in patients with quiescent ulcerative colitis. Gut 2006, 55:1768-1773.
40. Neumann H., Vieth M., Grauer M., et al. Virtual chromoendoscopy with I-Scan enables more precise diagnosis of mucosal inflammation in patients with inflammatory bowel disease. Gastrointestinal Endoscopy 2011, 73:AB381.
41. Li C.Q., Xie X.J., Yu T., et al. Classification of inflammation activity in ulcerative colitis by confocal laser endomicroscopy. American Journal of Gastroenterology 2010, 105:1391-1396.
42. Neumann H., Vieth M., Raithel M., et al. Confocal laser endomicroscopy in patients with Crohn's disease. Gastrointestinal Endoscopy 2011, 71:AB342.
43. Neumann H., Atreya R., Vieth M. Endocytoscopy enables accurate differentiation of mucosal inflammatory cells. Zeitschrift fur Gastroenterologie 2010, 48:4.
44. Mader R., Keystone E. Optimizing treatment with biologics. Journal of Rheumatology. Supplement 2007, 80:16-24.
45. Sandborn W., Colombel J.F., Lomax K., et al. American Journal of Gastroenterology 2010, 105(Suppl.):S442-S443.
46. Panaccione R., Rutgeerts P., Sandborn W.J., et al. Review article: Treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease. Alimentary Pharmacology and Therapeutics 2008, 28:674-688.
47. D'Haens G., Baert F., Van Assche G., et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008, 371:660-667.
48. Sandborn W.J., Van Assche G., Reinisch W., et al. Induction and maintenance of clinical remission by adalimumb in patients with moderate-to-severe ulcerative colitis. Journal of Crohn's and Colitis 2011, 5:P136.
49. Beaugerie L., Seksik P., Nion-Larmurier I., et al. Predictors of Crohn's disease. Gastroenterology 2006, 130:650-656.
50. Pariente B., Cosnes J., Danese S., et al. Development of the Crohn's disease digestive damage score, the Lèmann score. Inflammatory Bowel Diseases 2011, 17:1415-1422.
51. Sandborn W.J., Rutgeerts P., Feagan B.G., et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology 2009, 137:1250-1260.